Search results
Showing 6121 to 6135 of 7706 results
New price deal paves way for NICE approval of treatment for rare genetic condition
A new treatment for Duchenne muscular dystrophy (DMD) is set to be available to around 1,700 people in England following positive final draft guidance from NICE published today.
We explore the ongoing debate around NICE’s cost-effectiveness thresholds and what the future holds.
Should NICE's cost-effectiveness thresholds change? We explore the ongoing debate around NICE's cost-effectiveness thresholds and what the future...
Dr Patterson, a GP working on the frontline of primary care, describes why he is encouraged by NICE's approval of tirzepatide (Mounjaro).
Updated menopause guidance includes discussion aid to support conversations about HRT
Our updated guideline on menopause emphasises the importance of an individualised approach and shared decision-making when making choices about treatment for symptoms.
Our NICE talks podcasts bring you the real life experiences of people working within the NHS, public health and social care.
Public consultation launched on changes to NICE's Highly Specialised Technologies routing criteria
NICE is proposing changes to its routing criteria for Highly Specialised Technologies (HST) to ensure more consistent, predictable and transparent decisions.
Over 1000 people with advanced breast cancer set to benefit from new once-a-day tablet
We’ve issued final draft guidance recommending a new once-a-day tablet that is set to benefit around 1,100 people with a type of advanced breast cancer.
Our in-depth articles explore how our work is making a real difference to people's lives.
NICE recommends new treatment to prevent and reduce hearing loss in people being treated for cancer
For the first time, NICE has recommended an innovative new treatment to help stop babies, children and young people who are undergoing cancer treatment from losing their hearing.
NICE recommends new treatment to prevent and reduce hearing loss in people being treated for cancer For the first time, NICE has recommended an...
NICE describes how weight loss drug tirzepatide will be rolled out
The medication will initially be offered only to those people with the highest clinical needs.
NICE joins the shared commitment to public involvement in research
Working alongside people and communities is an essential tool in helping to improve?the impact of our guidance and continuing to get the best care to people and communities, fast, while ensuring value for the taxpayer.
Our updated guideline to improve the diagnosis of endometriosis
The guideline makes new recommendations and updates existing ones on diagnosing and managing a condition that affects approximately 1.5 million women of reproductive age in the UK.
NICE responds to failure of talks to reach price agreement on Enhertu
Talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged.